There have been great advances in the therapy of
cancer and leukemia. However, there are still many
Larionova, I.,
Tuguzbaeva, G.,
Ponomaryova, A.,
Stakheyeva, M.,
Cherdyntseva, N.,
V.N. Pavlov,
Choinzonov, E.,
Kzhyshkowska, J. (2020) -specific macrophages and from newly recruited monocytes. TAMs’ variability strongly depends on
cancer type, stage
Длинные некодирующие РНК: какие перспективы? conditions, including
cancer. The perception of lncRNAs as fragments of RNA and transcriptional noise has
The question of what came first—in this case the diagnosis of prostate
cancer or its therapy
NIKITIN, A.G.,
CHUDAKOVA, D.A.,
ENIKEEV, R.F.,
GORDIEV, M.G.,
SAKAEVA, D.,
DRUZHKOV, M.,
SHIGAPOVA, L.H.,
BROVKINA, O.I.,
SHAGIMARDANOVA, E.I.,
GUSEV, O.A. (2020) cell to tolerate high mutation burden—is one of the drivers of
cancer. Genome instability results from